G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

It’s hard to turn on the TV these days without seeing ads for drugs like Ozempic, Wegovy, Zepbound or Mounjaro. These ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.

A Columbia University dermatologist argues that physicians in her specialty should be on the lookout for metabolic syndrome ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Some people shed the kilos on semaglutide but regain all the lost weight when they get off the drug. Researchers are working ...